Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROTOPIC vs ENVARSUS XR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tacrolimus, a calcineurin inhibitor, binds to FKBP-12 and inhibits calcineurin, thereby blocking dephosphorylation and nuclear translocation of NFAT, reducing transcription of pro-inflammatory cytokines (e.g., IL-2, IFN-γ) in T-cells.
Calcineurin inhibitor. Binds to FKBP-12, forming a complex that inhibits calcineurin phosphatase, thereby blocking T-cell activation and IL-2 transcription.
Moderate to severe atopic dermatitis in non-immunocompromised patients where conventional therapy is inadvisable or ineffective,Prophylaxis of organ rejection in kidney or liver transplantation (systemic use, not topical),Off-label: Treatment of vitiligo, psoriasis, eczema of the face and neck (short-term)
Prophylaxis of organ rejection in kidney transplant patients,Prophylaxis of organ rejection in liver transplant patients
Apply a thin layer of 0.03% or 0.1% ointment to affected areas twice daily. Discontinue when lesions resolve. For adults, use 0.03% or 0.1%; 0.1% is not indicated for children.
0.2 mg/kg/day orally once daily, with the morning meal, using extended-release tablets. Dose adjustments guided by trough concentrations.
Terminal half-life ranges from 6–20 hours in pediatric atopic dermatitis patients; prolonged in hepatic impairment (mean 8–35 hours).
Terminal half-life approximately 25-30 hours in stable renal transplant patients. Longer half-life (up to 50 hours) in patients with hepatic impairment.
Primarily hepatic via CYP3A4; also metabolized by CYP3A5. Topical absorption results in minimal systemic exposure, but systemic metabolism follows oral route.
Primarily hepatic via CYP3A4 and CYP3A5; also metabolized by intestinal CYP3A4.
Primarily fecal (biliary) elimination of metabolites; <1% of parent drug excreted unchanged in urine.
Primarily fecal (94%) with minor renal excretion (2.2% as unchanged drug). Biliary excretion is a significant route.
99% bound primarily to albumin and alpha-1-acid glycoprotein.
Approximately 99% bound to erythrocytes and plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Vd/F ~ 30–50 L/kg after oral administration, indicating extensive tissue distribution; topical absorption negligible.
0.9-1.4 L/kg in renal transplant patients; large volume indicates extensive tissue distribution, particularly to red blood cells.
Systemic bioavailability after topical application is <0.5% in adults with intact skin; increases in compromised skin barrier.
Oral bioavailability is approximately 15-25% with the extended-release formulation; reduced by high-fat meal, so should be taken consistently on an empty stomach.
No dose adjustment required. Tacrolimus is not significantly renally excreted and systemic absorption is minimal.
No specific GFR-based dose adjustment; however, due to nephrotoxicity, monitor renal function closely and reduce dose if renal impairment occurs. For patients with severe renal impairment (Cr Cl <30 m L/min), consider alternative immunosuppression.
No specific dose adjustment for Child-Pugh class A or B. For severe hepatic impairment (Child-Pugh C), use with caution; consider starting at lower concentration (0.03%) due to potential increased systemic exposure.
In patients with mild to moderate hepatic impairment (Child-Pugh A or B), reduce dose by 25%. For severe hepatic impairment (Child-Pugh C), reduce dose by 50% and monitor trough levels closely.
Children (2-15 years): Apply 0.03% ointment twice daily. Do not use 0.1% in this age group. For children 2 years and older.
For pediatric kidney transplant recipients: 0.2 mg/kg/day orally once daily, with morning meal. Adjust to target trough concentrations. Safety and efficacy not established for other indications in pediatrics.
No specific dose adjustment required. Use minimum effective amount; monitor for cutaneous infections.
No specific dose adjustment; however, elderly patients may have increased susceptibility to nephrotoxicity and neurotoxicity. Use lowest effective dose, monitor renal function, and adjust based on trough levels.
Long-term safety of topical calcineurin inhibitors has not been established. Although a causal relationship has not been established, rare cases of malignancy (e.g., lymphoma, skin cancer) have been reported in patients treated with topical calcineurin inhibitors. Therefore, continuous long-term use should be avoided, and application should be limited to areas of involvement.
Increased susceptibility to infection and possible development of malignancy (e.g., lymphoma, skin cancer).
Increased risk of infections (including herpes simplex, eczema herpeticum); avoid use on malignant or premalignant skin conditions; use with caution in patients with netherton syndrome; may cause photosensitivity; avoid concurrent UV exposure; monitor for lymphadenopathy; not for use in children <2 years (safety not established).
Nephrotoxicity, neurotoxicity, hypertension, hyperkalemia, post-transplant diabetes mellitus, monitoring of blood concentrations required.
Hypersensitivity to tacrolimus or any component of the formulation; use in patients with known or suspected malignancy at the application site; use in immunocompromised patients (relative).
Hypersensitivity to tacrolimus or any component of the formulation.
No known food interactions with topical PROTOPIC. However, if absorbed systemically (rare), grapefruit juice may increase tacrolimus levels; avoid excessive consumption of grapefruit juice while using PROTOPIC.
Grapefruit and grapefruit juice increase tacrolimus exposure and must be avoided. High-fat meals may decrease absorption; consistency of food intake relative to dosing is recommended. Alcohol should be limited due to potential additive hepatotoxicity.
Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at systemic exposures below human therapeutic levels. No adequate human studies in pregnant women. Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. First trimester: avoid if possible. Second and third trimesters: limited data; systemic absorption minimal with topical use, but theoretical risk remains.
Envarsus XR (tacrolimus) is classified as FDA Pregnancy Category C. In the first trimester, there is an increased risk of congenital anomalies (e.g., cardiac, renal) based on animal studies; human data are limited but suggest a possible small increase. During the second and third trimesters, risks include intrauterine growth restriction, preterm delivery, and transient neonatal hyperkalemia and renal dysfunction. Advise women of childbearing potential to use effective contraception.
Not known if tacrolimus is excreted in human milk after topical administration. Systemic absorption is minimal (<0.5%), but caution is advised due to potential for infant immunosuppression. M/P ratio: not available. Consider benefit of breast-feeding vs risk of infant exposure.
Tacrolimus is excreted into human breast milk. The milk-to-plasma ratio is approximately 0.5 (range 0.12–0.75). Infant exposure is estimated to be <1% of the maternal weight-adjusted dose, which is considered low. However, due to potential for immunosuppression and adverse effects, breastfeeding is generally not recommended unless benefits outweigh risks. Monitor infant for signs of immunosuppression.
No specific dose adjustments recommended for topical use due to minimal systemic absorption. However, limit application to smallest area and shortest duration needed. Avoid use on large areas, broken skin, or under occlusion to reduce systemic exposure.
Pregnancy induces pharmacokinetic changes including increased volume of distribution, altered protein binding, and enhanced clearance of tacrolimus. Frequent monitoring of trough concentrations is essential to maintain therapeutic levels (target 5–10 ng/m L). Dose adjustments (increases of 20–50% or more) are often required, especially during the second and third trimesters. Postpartum, doses should be reduced to pre-pregnancy levels within 1–2 weeks.
PROTOPIC (tacrolimus) is a topical calcineurin inhibitor used for atopic dermatitis. It is steroid-sparing, thus avoiding skin atrophy and tachyphylaxis. Apply as a thin layer to affected areas. Avoid occlusive dressings. Can be used on face, neck, and intertriginous areas where topical steroids are riskier. Monitor for burning/stinging upon application, which often improves with continued use. Warn patients about rare risk of lymphoma and skin malignancy; use only as second-line therapy for short-term and intermittent treatment. Do not use in immunocompromised patients or those with active skin infections.
ENVARSUS XR is an extended-release formulation of tacrolimus; conversion from immediate-release tacrolimus requires close therapeutic drug monitoring due to altered pharmacokinetics. Administer consistently with or without food to minimize variability. Avoid grapefruit products. Monitor renal function, blood pressure, electrolytes, glucose, and trough tacrolimus levels. CYP3A4/5 inducers/inhibitors significantly affect tacrolimus exposure; adjust dose accordingly. Do not crush, chew, or split tablets.
Apply PROTOPIC exactly as prescribed; do not use more than directed.,Wash hands after application unless treating hands.,Do not cover treated area with bandages or dressings unless instructed.,Expect mild burning or stinging especially in the first few days; this usually resolves with continued use.,Avoid sun exposure and use sunscreen; protect treated areas from natural and artificial sunlight.,Do not use on infected skin; tell your doctor if you have an infection.,PROTOPIC is for external use only; do not get in eyes, mouth, or nose.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Store at room temperature away from moisture and heat.,Report any signs of skin infection, rash, or swollen lymph nodes to your doctor immediately.
Take exactly as prescribed, at the same time each day, with or without food but consistently.,Swallow whole; do not crush, chew, or break the tablet.,Avoid grapefruit and grapefruit juice.,Do not stop or change dose without consulting your doctor.,Report signs of infection (fever, sore throat), tremor, headache, changes in urination, or unusual bleeding.,Avoid live vaccines and limit sun exposure due to increased skin cancer risk.,Keep all appointments for blood tests to monitor drug levels and organ function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROTOPIC vs ENVARSUS XR, answered by our medical review team.
PROTOPIC is a Topical Calcineurin Inhibitor that works by Tacrolimus, a calcineurin inhibitor, binds to FKBP-12 and inhibits calcineurin, thereby blocking dephosphorylation and nuclear translocation of NFAT, reducing transcription of pro-inflammatory cytokines (e.g., IL-2, IFN-γ) in T-cells.. ENVARSUS XR is a Calcineurin Inhibitor Immunosuppressant that works by Calcineurin inhibitor. Binds to FKBP-12, forming a complex that inhibits calcineurin phosphatase, thereby blocking T-cell activation and IL-2 transcription.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROTOPIC and ENVARSUS XR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROTOPIC is: Apply a thin layer of 0.03% or 0.1% ointment to affected areas twice daily. Discontinue when lesions resolve. For adults, use 0.03% or 0.1%; 0.1% is not indicated for children.. The standard adult dose of ENVARSUS XR is: 0.2 mg/kg/day orally once daily, with the morning meal, using extended-release tablets. Dose adjustments guided by trough concentrations.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROTOPIC and ENVARSUS XR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROTOPIC is classified as Category C. Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at systemic exposures below human therapeutic levels. No adequate human studies in pregnant women.. ENVARSUS XR is classified as Category C. Envarsus XR (tacrolimus) is classified as FDA Pregnancy Category C. In the first trimester, there is an increased risk of congenital anomalies (e.g., cardiac, renal) based on anima. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.